Cellular immunotherapy licensed for advanced prostate cancer.
作者信息
Traynor Kate
出版信息
Am J Health Syst Pharm. 2010 Jun 1;67(11):862. doi: 10.2146/news100039.
PMID:20484204
Abstract
摘要
相似文献
1
Cellular immunotherapy licensed for advanced prostate cancer.
Am J Health Syst Pharm. 2010 Jun 1;67(11):862. doi: 10.2146/news100039.
2
New treatments for metastic prostate cancer.
Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70.
3
Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
Issues Emerg Health Technol. 2007 Sep(101):1-4.
4
Immunotherapy: a new option for advanced prostate cancer.
Harv Mens Health Watch. 2010 Sep;15(2):1-2.
5
Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
J Contemp Health Law Policy. 2008 Fall;25(1):107-41.
6
Therapy: An immune one-two punch.
Nature. 2015 Dec 17;528(7582):S134-6. doi: 10.1038/528S134a.
7
Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Curr Opin Urol. 2017 Nov;27(6):566-571. doi: 10.1097/MOU.0000000000000433.
8
Landmark approval for Dendreon's cancer vaccine.
Nat Biotechnol. 2010 Jun;28(6):531-2. doi: 10.1038/nbt0610-531.
9
Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.
10
Clinical development of immunotherapy for prostate cancer.
Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21.
Zotero 插件